DK2739153T3 - TREATMENT OF BREAST CANCER - Google Patents

TREATMENT OF BREAST CANCER Download PDF

Info

Publication number
DK2739153T3
DK2739153T3 DK12846720.6T DK12846720T DK2739153T3 DK 2739153 T3 DK2739153 T3 DK 2739153T3 DK 12846720 T DK12846720 T DK 12846720T DK 2739153 T3 DK2739153 T3 DK 2739153T3
Authority
DK
Denmark
Prior art keywords
compound
breast cancer
cells
inhibitors
dht
Prior art date
Application number
DK12846720.6T
Other languages
Danish (da)
English (en)
Inventor
Dawn Cochrane
Jennifer Richer
Andrew A Protter
Original Assignee
Medivation Prostate Therapeutics Llc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2739153(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc, Univ Colorado Regents filed Critical Medivation Prostate Therapeutics Llc
Application granted granted Critical
Publication of DK2739153T3 publication Critical patent/DK2739153T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12846720.6T 2011-07-29 2012-07-27 TREATMENT OF BREAST CANCER DK2739153T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
DK2739153T3 true DK2739153T3 (en) 2018-12-03

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12846720.6T DK2739153T3 (en) 2011-07-29 2012-07-27 TREATMENT OF BREAST CANCER

Country Status (18)

Country Link
US (4) US9517229B2 (https=)
EP (4) EP3430907A1 (https=)
JP (2) JP6158180B2 (https=)
KR (1) KR101923250B1 (https=)
CN (1) CN103997894B (https=)
BR (1) BR112014002200A2 (https=)
CA (1) CA2843417C (https=)
CY (1) CY1121038T1 (https=)
DK (1) DK2739153T3 (https=)
EA (1) EA028452B1 (https=)
ES (1) ES2696074T3 (https=)
HU (1) HUE040524T2 (https=)
MX (1) MX359664B (https=)
PH (1) PH12014500248B1 (https=)
PL (1) PL2739153T3 (https=)
PT (1) PT2739153T (https=)
SI (1) SI2739153T1 (https=)
WO (1) WO2013066440A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
SG11201704425TA (en) * 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP4644737B2 (ja) 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
KR101456722B1 (ko) * 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
NZ594741A (en) * 2009-02-24 2014-03-28 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011022316A1 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
US10175240B2 (en) 2012-08-23 2019-01-08 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
EP3791724A1 (en) 2021-03-17
PT2739153T (pt) 2018-11-28
PH12014500248B1 (en) 2018-08-31
WO2013066440A1 (en) 2013-05-10
EA028452B1 (ru) 2017-11-30
JP2014524934A (ja) 2014-09-25
US9517229B2 (en) 2016-12-13
HK1198867A1 (en) 2015-06-19
JP6158180B2 (ja) 2017-07-05
JP2017141269A (ja) 2017-08-17
EP3430907A1 (en) 2019-01-23
EA201400178A1 (ru) 2014-11-28
PH12014500248A1 (en) 2014-03-17
CY1121038T1 (el) 2019-12-11
US20190262315A1 (en) 2019-08-29
MX359664B (es) 2018-10-05
ES2696074T3 (es) 2019-01-14
HK1201413A1 (en) 2015-09-04
EP2739153B1 (en) 2018-08-22
CN103997894B (zh) 2016-08-24
HUE040524T2 (hu) 2019-03-28
SI2739153T1 (sl) 2018-12-31
CA2843417A1 (en) 2013-05-10
BR112014002200A2 (pt) 2017-03-07
US10111861B2 (en) 2018-10-30
US20140296312A1 (en) 2014-10-02
PL2739153T3 (pl) 2019-04-30
KR101923250B1 (ko) 2018-11-28
KR20140107174A (ko) 2014-09-04
EP3610731A1 (en) 2020-02-19
US20170087132A1 (en) 2017-03-30
CN103997894A (zh) 2014-08-20
WO2013066440A9 (en) 2013-07-18
CA2843417C (en) 2018-08-21
EP2739153A4 (en) 2015-03-11
MX2014001218A (es) 2014-08-22
EP2739153A1 (en) 2014-06-11
US20210069154A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
DK2739153T3 (en) TREATMENT OF BREAST CANCER
AU2016256471B2 (en) Methods of treating cancer
CA2861056A1 (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
EP4119557A1 (en) Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
HK1198867B (en) Treatment of breast cancer
CA2894153A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
WO2018195202A1 (en) Compositions and methods for the treatment of cancer
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
WO2022238706A1 (en) Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
HK40046131A (en) Quinoline derivative used for treating small cell lung cancer
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤